Companies › Tessera Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TSRA-196 In-vivo genome editing via lipid nanoparticles to increase alpha-1 antitrypsin expression | SERPINA1 | Phase 1 | Alpha-1 Antitrypsin Deficiency (AATD) | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07227207 | TSRA-196 | Phase 1 | Alpha-1 Antitrypsin Deficiency (AATD) | Metabolic and endocrine | Mar 2029 |
Krystal Biotech Takeda Wave Life Sciences USA Beam Therapeutics Grifols Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.